Trial Profile

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Advanced breast cancer; Bladder cancer; Brain cancer; Cancer; Cervical cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Parotid cancer; Prostate cancer; Thyroid cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms 1-2018 BSMO; Precision 2 - Olaparib

Most Recent Events

19 Aug 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
19 Aug 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
19 Aug 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com